NEUP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neuphoria Therapeutics Inc (NEUP) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. The company's financial performance is weak, with no revenue growth and significant losses. Analyst sentiment has turned cautious due to increased risk following a Phase 3 trial failure. Technical indicators suggest no clear entry point, and there are no recent positive news or trading trends to support a buy decision. Given the lack of strong positive catalysts and the absence of proprietary trading signals, it is better to hold off on investing in NEUP at this time.
The MACD is slightly positive but contracting, RSI is neutral at 65.675, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 4.241, with resistance at 4.447 and support at 4.035. Overall, the technical indicators do not suggest a strong buy signal.
The company has positive Phase 2b data for post-traumatic stress disorder, which may provide some long-term value.
The failure of the Phase 3 trial for social anxiety disorder has significantly increased the company's risk profile. Analysts have lowered the price target from $21 to $7, citing challenges. Financial performance remains weak with no revenue growth and substantial losses.
In Q1 2026, revenue remained at 0 with no growth. Net income improved to -$9,906,504, up 1130.95% YoY, but remains negative. EPS is -4.41 with no improvement YoY. Gross margin is 0%. Overall, the financials indicate a struggling company with no clear growth trajectory.
H.C. Wainwright maintains a Buy rating but has significantly lowered the price target from $21 to $7, citing increased risk due to the Phase 3 trial failure. Analysts acknowledge some value from positive Phase 2b data but remain cautious overall.
